Aspen Pharmacare Holdings has reported financial results for the year ended 30 June 2025, with strong momentum in Commercial Pharmaceuticals and a modified Manufacturing strategy.
Aspen Pharmacare Holdings has reported financial results for the year ended 30 June 2025, with strong momentum in Commercial Pharmaceuticals and a modified Manufacturing strategy.
The true heroes of our Mandela Day campaign are our employees who continue to volunteer to make a difference through their acts of selfless generosity, humility and care for those in need.
Aspen Pharmacare Holdings has reported positive Group interim financial results for the six months ended 31 December 2024.
Aspen has announced the availability of Lilly’s tirzepatide, marketed globally as Mounjaro®, a therapeutic option available to physicians for the treatment of Type II diabetes.
Aspen and SEMDSA earlier today raised awareness around the alarming rise of non-communicable diseases, particularly diabetes, in recognition of World Diabetes Day.
Aspen’s Stephen Saad and Sean Capazorio will take part in Investec’s CEO conference in London from 14 to 15 November 2024.
Aspen has contributed towards the funding of a new mobile cancer screening clinic for rural and peri-urban disadvantaged communities.
JSE-listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, has reported solid Group financial results for the year ended 30 June 2024.
Aspen Holdings
www.aspenpharma.com
Hotline (South Africa)
0800 122 912
Medical Careline (South Africa) 0800 118 088
